Background: We aimed to estimate real-world evidence of the prevalence rate of genetic developmental and epileptic encephalopathies (DEEs) in the Italian population over a 11-year period. Methods: Fifteen paediatric and adult tertiary Italian epilepsy centres participated in a survey related to 98 genes included in the molecular diagnostic workflows of most centres. We included patients with a clinical diagnosis of DEE, caused by a pathogenic or likely pathogenic variant in one of the selected genes, with a molecular diagnosis established between 2012 and 2022. These data were used as a proxy to estimate the prevalence rate of DEEs. Results: We included 1568 unique patients and found a mean incidence proportion of 2.6 patients for 100.000 inhabitants (SD=1.13) with consistent values across most Italian regions. The number of molecular diagnoses showed a continuing positive trend, resulting in more than a 10-fold increase between 2012 and 2022. The mean age at molecular diagnosis was 11.2 years (range 0-75). Pathogenic or likely pathogenic variants in genes with an autosomal dominant inheritance pattern occurred in 77% (n=1207) patients; 17% (n=271) in X-linked genes and 6% (n=90) in genes with autosomal recessive inheritance. The most frequently reported genes in the survey were SCN1A (16%), followed by KCNQ2 (5.6%) and SCN2A (5%). Conclusion: Our study provides a large dataset of patients with monogenic DEE, from a European country. This is essential for informing decision-makers in drug development on the appropriateness of initiatives aimed at developing precision medicine therapies and is instrumental in implementing disease-specific registries and natural history studies.
National survey on the prevalence of single-gene aetiologies for genetic developmental and epileptic encephalopathies in Italy / Mei, Davide; Balestrini, Simona; Parrini, Elena; Gambardella, Antonio; Annesi, Grazia; De Giorgis, Valentina; Gana, Simone; Bassi, Maria Teresa; Zucca, Claudio; Elia, Maurizio; Vetri, Luigi; Castellotti, Barbara; Ragona, Francesca; Mastrangelo, Mario; Pisani, Francesco; D'Orsi, Giuseppe; Carella, Massimo; Pruna, Dario; Giglio, Sabrina; Marini, Carla; Cesaroni, Elisabetta; Riva, Antonella; Scala, Marcello; Licchetta, Laura; Minardi, Raffaella; Contaldo, Ilaria; Gambardella, Maria Luigia; Cossu, Alberto; Proietti, Jacopo; Cantalupo, Gaetano; Trivisano, Marina; De Dominicis, Angela; Specchio, Nicola; Tassi, Laura; Guerrini, Renzo. - In: JOURNAL OF MEDICAL GENETICS. - ISSN 0022-2593. - (2024), pp. 1-7. [10.1136/jmg-2024-110328]
National survey on the prevalence of single-gene aetiologies for genetic developmental and epileptic encephalopathies in Italy
Mastrangelo, Mario;Pisani, Francesco;Proietti, Jacopo;Cantalupo, Gaetano;Guerrini, Renzo
2024
Abstract
Background: We aimed to estimate real-world evidence of the prevalence rate of genetic developmental and epileptic encephalopathies (DEEs) in the Italian population over a 11-year period. Methods: Fifteen paediatric and adult tertiary Italian epilepsy centres participated in a survey related to 98 genes included in the molecular diagnostic workflows of most centres. We included patients with a clinical diagnosis of DEE, caused by a pathogenic or likely pathogenic variant in one of the selected genes, with a molecular diagnosis established between 2012 and 2022. These data were used as a proxy to estimate the prevalence rate of DEEs. Results: We included 1568 unique patients and found a mean incidence proportion of 2.6 patients for 100.000 inhabitants (SD=1.13) with consistent values across most Italian regions. The number of molecular diagnoses showed a continuing positive trend, resulting in more than a 10-fold increase between 2012 and 2022. The mean age at molecular diagnosis was 11.2 years (range 0-75). Pathogenic or likely pathogenic variants in genes with an autosomal dominant inheritance pattern occurred in 77% (n=1207) patients; 17% (n=271) in X-linked genes and 6% (n=90) in genes with autosomal recessive inheritance. The most frequently reported genes in the survey were SCN1A (16%), followed by KCNQ2 (5.6%) and SCN2A (5%). Conclusion: Our study provides a large dataset of patients with monogenic DEE, from a European country. This is essential for informing decision-makers in drug development on the appropriateness of initiatives aimed at developing precision medicine therapies and is instrumental in implementing disease-specific registries and natural history studies.File | Dimensione | Formato | |
---|---|---|---|
jmg-2024-110328.full.pdf
solo gestori archivio
Note: Mei_National survey_2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
584.6 kB
Formato
Adobe PDF
|
584.6 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.